摘要
目的分析磷酸西格列汀+二甲双胍治疗2型糖尿病(type 2 diabetes mellitus,T2DM)的临床效果。方法选择2019年5月—2022年11月新沂市中医医院门诊接诊的62例T2DM患者,以随机数表法分为对照组(31例,二甲双胍治疗)和观察组(31例,二甲双胍+磷酸西格列汀治疗)。比较两组血糖水平、胰岛素指标、不良反应。结果用药后,观察组空腹血糖(FPG)、餐后2 h血糖(2 hPG)及糖化血红蛋白(HbA1c)分别为(6.12±1.20)mmol/L、(7.81±1.02)mmol/L、(6.82±0.70)%,均低于对照组的(7.83±1.31)mmol/L、(8.93±1.12)mmol/L、(7.67±0.82)%,差异有统计学意义(t=5.359、4.116、4.390,P<0.05)。观察组空腹胰岛素(FINS)高于对照组,胰岛素抵抗指数(HOMA-IR)低于对照组,差异有统计学意义(t=3.942、10.962,P<0.05)。观察组不良反应发生率9.68%与对照组6.45%比较,差异无统计学意义(χ^(2)=0.000,P>0.05)。结论磷酸西格列汀+二甲双胍治疗T2DM效果确切,可有效控制患者血糖,改善其胰岛素抵抗程度,且安全性高。
Objective To analyze the clinical effect of sitagliptin phosphate+metformin in the treatment of type 2 diabetes mellitus(T2DM).Methods Sixty-two patients with type 2 diabetes mellitus(T2DM)who were admitted to the outpatient service of Xinyi Traditional Chinese Medicine Hospital from May 2019 to November 2022 were selected and randomly divided into control group(31 cases,treated with metformin)and observation group(31 cases,treated with metformin+sitagliptin phosphate).The blood glucose level,insulin index and adverse reactions were compared between the two groups.Results After administration,the fasting plasma glucose(FPG),2 h-postprandial blood glucose(2 hPG)and glycosylated hemoglobin(HbA1c)in the observation group were(6.12±1.20)mmol/L,(7.81±1.02)mmol/L,(6.82±0.70)%,respectively,which were lower than those in the control group(7.83±1.31)mmol/L,(8.93±1.12)mmol/L,(7.67±0.82)%,and the difference was statistically significant(t=5.359,4.116,4.390,P<0.05).The fasting insulin(FINS)in the observation group was higher than that in the control group,and the insulin resistance index(HOMA-IR)was lower than that in the control group,the difference was statistically significant(t=3.942,10.962,P<0.05).The incidence of adverse reactions in the observation group was 9.68%,compared with 6.45%in the control group,and the difference was not statistically significant(χ^(2)=0.000,P>0.05).Conclusion Sitagliptin phosphate+metformin is effective in the treatment of T2DM,which can effectively control patients'blood glucose and improve their insulin resistance,and has high safety.
作者
陈停停
石春明
苏晓辉
CHEN Tingting;SHI Chunming;SU Xiaohui(Department of Internal Medicine Outpatient Clinic,Xinyi Traditional Chinese Medicine Hospital,Xinyi,Jiangsu Province,221400 China;Department of Geriatrics,Xinyi Traditional Chinese Medicine Hospital,Xinyi,Jiangsu Prov-ince,221400 China;Department of Endocrinology,Xinyi Traditional Chinese Medicine Hospital,Xinyi,Jiangsu Prov-ince,221400 China)
出处
《糖尿病新世界》
2023年第3期108-110,114,共4页
Diabetes New World Magazine
关键词
磷酸西格列汀
二甲双胍
2型糖尿病
胰岛素
不良反应
Sitagliptin phosphate
Metformin
Type 2 diabetes mellitus
Insulin
Adverse effects
